Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $34
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $32 to $34.
Baird analyst Joel Beatty maintains Denali Therapeutics (NASDAQ:DNLI) with a Outperform and raises the price target from $32 to $34.